Buzz Stocks: Charter, BioCryst, and Lorillard, Inc.

Today's stocks to watch in the news include Charter Communications, Inc. (CHTR), BioCryst Pharmaceuticals, Inc. (BCRX), and Lorillard Inc. (LO)

Mar 31, 2015 at 9:22 AM
facebook twitter linkedin

U.S. benchmarks are poised to pare a portion of yesterday's massive gains, with futures pointed lower on the last day of the first quarter. Among specific equities in focus are cable service provider Charter Communications, Inc. (NASDAQ:CHTR), drug developer BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and tobacco titan Lorillard Inc. (NYSE:LO).

  • M&A activity ruled the Street on Monday, and today it's CHTR in the spotlight. The company announced it will purchase Bright House Networks for roughly $10 billion. The deal will allow the latter's owner, Advance Newhouse, to become the former's biggest shareholder, and is contingent upon U.S. regulators approving the merger between Comcast Corporation (NASDAQ:CMCSA) and Time Warner Inc (NYSE:TWX). The news is being well-received, with shares of CHTR up 6.9% in electronic trading -- and headed for a fresh record high. Longer term, Charter Communications, Inc. has added 48.9% over the past 52 weeks, and settled last night at $183.39. In the options pits, long calls have been popular, per CHTR's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 4.37, which ranks in the 76th annual percentile.

  • BCRX is also signaling a strong start, with the shares 6.2% higher ahead of the bell. Stoking the buying power is news the firm landed a multi-million-dollar contract with the U.S. government to continue advancing possible treatments for various viral diseases, including Ebola. On the charts, the security has been making a series of lower lows throughout 2015 -- translating into a loss of 29.5% -- and closed Monday at $8.57. Against this backdrop, sentiment has been skewed toward the skeptical side. At the ISE, CBOE, and PHLX, BCRX's 10-day put/call volume ratio of 1.53 rests higher than 90% of all similar readings taken in the past year. Elsewhere, although short interest plunged 17% in the latest reporting period, it still accounts for a lofty 23.9% of BioCryst Pharmaceuticals, Inc.'s float.

  • LO is down 2.5% in pre-market trading, amid speculation the Federal Trade Commission (FTC) is looking to block the merger between the tobacco company and its peer Reynolds American, Inc. (NYSE:RAI). The reports are unconfirmed, and a meeting between LO, RAI, and federal regulators is rumored to be slated for this week. Since taking a sharp bounce off their 160-day moving average in mid-October, shares of LO have added 15.5% to trade at $66.42. However, today's projected price move could have the equity testing support atop its 80-day moving average. Options traders, meanwhile, have shown a preference for puts over calls among contracts expiring in three months or less. Specifically, Lorillard Inc.'s Schaeffer's put/call open interest ratio (SOIR) of 1.59 ranks in the 68th percentile of its annual range.

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 


300x250 - Banner 3 - v1